PentixaPharm gets 15M euros for radiopharmaceutical trials

By staff writers

February 7, 2020 -- PentixaPharm has announced 15 million euros in funding to test a pair of radiopharmaceutical drugs to identify fast-progressing diseases, including cancer.

The series A funding round was led by Eckert Life Science Accelerator. The financing will help PentixaPharm test PentixaFor and PentixaTher, a pair of radiopharmaceuticals that target the chemokine receptor CXCR4.

The funding will specifically be used for a phase II trial of PentixaFor and a phase I trial of PentixaTher in central nervous system lymphoma. PentixaPharm will also use the funds to support proof-of-concept studies.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking